Complement system Ficolin 3 WIESLAB®

Add to my product list

The increased awareness and interest in the complement system has augmented the need for a simple and objective method to assess the function of complement activity.

With the Euro Diagnostica complement assay solution a complete picture of the complement function is provided.

Complement System Website

Read more about the complement system, details related to the diagnostics, treatment and multiple applications on our new dedicated Complement System Website!

Product code
COMPL F3 RUO
Format
ELISA
Tests
Break apart microtitration strips (12x8) 96 wells
Calculation
Qualitative
Calibrators
Refer
Incubation time
60+30+30 min
Detection system
405 nm
Availability
Research use only

Purpose of research product

The Wieslab® Complement Ficolin 3 kit is an enzyme immunoassay for the qualitative determination of Ficolin 3 complement pathway in human serum. The result shall not be used for clinical diagnosis or patient management.

Background

The complement system plays an essential role in chronic, autoimmune and infectious disease. There are three pathways of complement activation, namely the classical, the alternative and the MBL pathway.

Impaired complement activity causes humans to become susceptible to repetitive fulminant or severe infections and may contribute to development of autoimmune disease. Inappropriate activation of complement contributes to chronic inflammation and tissue injury.

 

Technical information

The Wieslab® Complement assay combines principles of the hemolytic assay for complement activation with the use of labeled antibodies specific for neoantigen produced as a result of complement activation. The amount of neoantigen generated is proportional to the functional activity of complement pathways.

In the Complement Ficolin3 kit the wells of the microtitre plate are coated with specific activators of the Ficolin 3 pathway. Patient serum is diluted in diluent containing specific blocker to ensure that only the Ficolin 3 pathway is activated. During the incubation of the diluted patient serum in the wells, complement is activated by the specific coating.

The wells are then washed and C5b-9 is detected with a specific alkaline phosphatase labelled antibody to the neoantigen expressed during MAC formation.

After a further washing step, detection of specific antibodies is obtained by incubation with alkaline phosphatase substrate solution. The amount of complement activation correlates with the colour intensity and is measured in terms of absorbance (optical density (OD)).

Kit components and storage of reagents

- One frame with 96 wells, coated with Acetylated BSA, covered with lid and sealed in a foil pack with a desiccation sachet.

- 35 mL Diluent F3 (Dil F3).

- 13 mL Conjugate containing alkaline phosphatase-labelled antibodies to C5b-9 (blue colour).

- 13 mL Substrate solution ready to use.

- 13 mL Stop solution ready to use.

- 30 mL Wash solution 30x concentrated.

- 0.2 mL Negative Control (NC) containing human serum (to be diluted as patient sample).

- 0.2 mL Positive Control (PC) containing freeze dried human serum, see “Reconstitution of positive control”, in the IFU.

 

All reagents in the kit are ready to use except washing solution and controls. All reagents except the positive control should be stored at 2-8° C.

The positive control should be stored at -20° C.